Skip to main content

Advertisement

SpringerLink
Log in

CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The clinical importance of CYP2D6 genotype as predictor of tamoxifen efficacy is still unclear. Recent genotyping studies on CYP2D6 using DNA derived from tumor blocks have been criticized because loss of heterozygosity (LOH) in tumors may lead to false genotype assignment. Postmenopausal early breast cancer patients who were randomized to receive tamoxifen, followed by exemestane in a large randomized controlled trial were genotyped for five CYP2D6 alleles. CYP2D6 genotypes and phenotypes were related to disease-free survival during tamoxifen use (DFS-t) in 731 patients. By analyzing microsatellites flanking the CYP2D6 gene, patients whose genotyping results were potentially affected by LOH were excluded. In addition, exploratory analyses on 24 genetic variants of other metabolic enzymes and the estrogen receptor were performed. For the CYP2D6 analysis, only 2.3 % of the samples were excluded, because influence of LOH could not be ruled out. No association was found between the CYP2D6 genotype or predicted phenotype and DFS-t (poor vs. extensive metabolizers: unadjusted hazard ratio 1.33, 95 % CI 0.52–3.43; P = 0.55). DFS-t was associated with UGT2B15*2 (Vt/Vt + Wt/Vt vs. Wt/Wt: adjusted hazard ratio 0.47, 95 % CI 0.25–0.89; P = 0.019) and the estrogen receptor-1 polymorphism ESR1 PvuII (gene–dose effect: adjusted hazard ratio 1.63, 95 % CI 1.04–2.54; P = 0.033). In postmenopausal early breast cancer patients treated with adjuvant tamoxifen followed by exemestane neither CYP2D6 genotype nor phenotype did affect DFS-t. This is in accordance with two recent studies in the BIG1-98 and ATAC trials. Our study is the first CYP2D6 association study using DNA from paraffin-embedded tumor tissue in which potentially false interpretation of genotyping results because of LOH was excluded. Polymorphisms in the estrogen receptor-1 and UGT2B15 may be associated with tamoxifen efficacy, but these findings need replication.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Desta Z, Ward BA, Soukhova NV, Flockhart DA (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310:1062–1075

    Article  PubMed  CAS  Google Scholar 

  2. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P et al (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758–1764

    Article  PubMed  CAS  Google Scholar 

  3. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH et al (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30–39

    Article  PubMed  CAS  Google Scholar 

  4. Lim YC, Desta Z, Flockhart DA, Skaar TC (2005) Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 55:471–478

    Article  PubMed  CAS  Google Scholar 

  5. Lim YC, Li L, Desta Z, Zhao Q, Rae JM, Flockhart DA et al (2006) Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther 318:503–512

    Article  PubMed  CAS  Google Scholar 

  6. Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, Spelsberg TC (2009) The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res 69:1722–1727

    Article  PubMed  CAS  Google Scholar 

  7. Murdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W et al (2011) Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 89:708–717. doi:10.1038/clpt.2011.27

    Article  PubMed  CAS  Google Scholar 

  8. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW et al (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312–9318

    Article  PubMed  CAS  Google Scholar 

  9. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S et al (2009) Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302:1429–1436

    Article  PubMed  CAS  Google Scholar 

  10. Dezentje VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H (2009) Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin Cancer Res 15:15–21

    Article  PubMed  CAS  Google Scholar 

  11. Lash TL, Lien EA, Sorensen HT, Hamilton-Dutoit S (2009) Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol 10:825–833

    Article  PubMed  CAS  Google Scholar 

  12. Dezentje VO, van Blijderveen NJ, Gelderblom H, Putter H, van Herk-Sukel MP, Casparie MK et al (2010) Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol 28:2423–2429

    Article  PubMed  CAS  Google Scholar 

  13. Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC et al (2010) Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 340:c693

    Article  PubMed  Google Scholar 

  14. Abraham JE, Maranian MJ, Driver KE, Platte R, Kalmyrzaev B, Baynes C et al (2010) CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res 12:R64

    Article  PubMed  Google Scholar 

  15. Goetz M, Berry D, Klein T, International Tamoxifen Pharmacogenomics Consortium (2009) Adjuvant tamoxifen treatment outcome according to cytochrome P450 2D6 (CYP2D6) phenotype in early stage breast cancer: findings from the International Tamoxifen Pharmacogenomics Consortium. Cancer Res 69:33

    Article  Google Scholar 

  16. Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R et al (2012) CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1–98 trial. J Natl Cancer Inst 104:441–451. doi:10.1093/jnci/djs125

    Article  PubMed  CAS  Google Scholar 

  17. Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP et al (2012) CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104:452–460. doi:10.1093/jnci/djs126

    Article  PubMed  CAS  Google Scholar 

  18. Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW et al (2011) Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 89:718–725. doi:10.1038/clpt.2011.32

    Article  PubMed  CAS  Google Scholar 

  19. Gjerde J, Hauglid M, Breilid H, Lundgren S, Varhaug JE, Kisanga ER et al (2008) Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol 19:56–61. doi:10.1093/annonc/mdm434

    Article  PubMed  CAS  Google Scholar 

  20. Nishiyama T, Ogura K, Nakano H, Ohnuma T, Kaku T, Hiratsuka A et al (2002) Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. Biochem Pharmacol 63:1817–1830

    Article  PubMed  CAS  Google Scholar 

  21. Sun D, Sharma AK, Dellinger RW, Blevins-Primeau AS, Balliet R, Chen G et al (2007) Glucuronidation of active tamoxifen metabolites by the human UDP-glucuronosyltransferases (UGTs). Drug Metab Dispos 35:2006–2014

    Article  PubMed  CAS  Google Scholar 

  22. Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, Kroetz DL, Flockhart DA (2012) Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1–98 trial. J Natl Cancer Inst 104:1264–1268. doi:10.1093/jnci/djs304

    Article  PubMed  CAS  Google Scholar 

  23. Pharoah PD, Abraham J, Caldas C (2012) Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1–98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104:1263–1264. doi:10.1093/jnci/djs312

    Article  PubMed  CAS  Google Scholar 

  24. Stanton V Jr (2012) Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1–98 trial. J Natl Cancer Inst 104:1265–1266. doi:10.1093/jnci/djs305

    Article  PubMed  CAS  Google Scholar 

  25. Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ (2012) Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet 14:23–34. doi:10.1038/nrg3352

    Article  PubMed  Google Scholar 

  26. Castells A, Gusella JF, Ramesh V, Rustgi AK (2000) A region of deletion on chromosome 22q13 is common to human breast and colorectal cancers. Cancer Res 60:2836–2839

    PubMed  CAS  Google Scholar 

  27. van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM et al (2011) Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377:321–331

    Article  PubMed  Google Scholar 

  28. Baak-Pablo R, Dezentje V, Guchelaar HJ, van der Straaten T (2010) Genotyping of DNA samples isolated from formalin-fixed paraffin-embedded tissues using preamplification. J Mol Diagn 12:746–749

    Article  PubMed  CAS  Google Scholar 

  29. Ahern TP, Christensen M, Cronin-Fenton DP, Lunetta KL, Rosenberg CL, Sorensen HT et al (2010) Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue. Clin Epidemiol 2:241–246. doi:10.2147/CLEP.S13811

    PubMed  Google Scholar 

  30. Rae JM, Sikora MJ, Henry NL, Li L, Kim S, Oesterreich S et al (2009) Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J 9:258–264

    Article  PubMed  CAS  Google Scholar 

  31. Thompson AM, Johnson A, Quinlan P, Hillman G, Fontecha M, Bray SE et al (2010) Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat 125:279–287

    Article  PubMed  Google Scholar 

  32. Kiyotani K, Mushiroda T, Hosono N, Tsunoda T, Kubo M, Aki F et al (2010) Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response. Pharmacogenet Genomics 20:565–568

    Article  PubMed  CAS  Google Scholar 

  33. Court MH, Hao Q, Krishnaswamy S, Bekaii-Saab T, Al-Rohaimi A, von Moltke LL et al (2004) UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. J Pharmacol Exp Ther 310:656–665

    Article  PubMed  CAS  Google Scholar 

  34. Ahern TP, Christensen M, Cronin-Fenton DP, Lunetta KL, Soiland H, Gjerde J et al (2011) Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors. Cancer Epidemiol Biomarkers Prev 20:1937–1943

    Article  PubMed  CAS  Google Scholar 

  35. Jin Y, Hayes DF, Li L, Robarge JD, Skaar TC, Philips S et al (2008) Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. J Clin Oncol 26:5849–5854

    Article  PubMed  Google Scholar 

  36. Onitilo AA, McCarty CA, Wilke RA, Glurich I, Engel JM, Flockhart DA et al (2009) Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. Breast Cancer Res Treat 115:643–650

    Article  PubMed  CAS  Google Scholar 

  37. Hayes DF, Skaar TC, Rae JM, Henry NL, Nguyen AT, Stearns V et al (2010) Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels: revised and updated results. Clin Pharmacol Ther 88:626–629. doi:10.1038/clpt.2010.143

    Article  PubMed  CAS  Google Scholar 

  38. van Duijnhoven FJ, Peeters PH, Warren RM, Bingham SA, Uitterlinden AG, van Noord PA et al (2006) Influence of estrogen receptor alpha and progesterone receptor polymorphisms on the effects of hormone therapy on mammographic density. Cancer Epidemiol Biomarkers Prev 15:462–467

    Article  PubMed  Google Scholar 

  39. Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW (2004) Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 96:621–628

    Article  PubMed  CAS  Google Scholar 

  40. Grabinski JL, Chisholm G, Smith LS, Drengler RL, Kalter S, Rodriguez G et al. (2008) ER alpha genotypes and breast cancer recurrence. J Clin Oncol 26(15S):501

    Google Scholar 

Download references

Acknowledgments

We would like to thank the women participating in the TEAM trial and Tom van Wezel for his intellectual contribution and assistance in the microsatellite analysis. The core TEAM trial was supported by an unrestricted research grant from Pfizer Inc. The current separate pharmacogenetic study was not financially supported. Pfizer had no role in writing of this manuscript or decision to submit.

Disclosure

The authors have declared no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Clinical Oncology, Leiden University Medical Center, PO Box 9600, 2300 RC, Leiden, The Netherlands

    V. O. Dezentjé, J. W. R. Nortier & H. Gelderblom

  2. Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands

    V. O. Dezentjé, J. M. Vletter-Bogaartz, T. van der Straaten, J. A. M. Wessels & H.-J. Guchelaar

  3. Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands

    R. H. N. van Schaik

  4. Department of Surgical Oncology, Leiden University Medical Center, Leiden, The Netherlands

    E. M.-K. Kranenbarg & C. J. H. van de Velde

  5. Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands

    E. M. Berns & C. Seynaeve

  6. Department of Medical Statistics, Leiden University Medical Center, Leiden, The Netherlands

    H. Putter

Authors
  1. V. O. Dezentjé
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. H. N. van Schaik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. M. Vletter-Bogaartz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. van der Straaten
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. A. M. Wessels
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. M.-K. Kranenbarg
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E. M. Berns
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C. Seynaeve
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H. Putter
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C. J. H. van de Velde
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J. W. R. Nortier
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. H. Gelderblom
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. H.-J. Guchelaar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Gelderblom.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 157 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dezentjé, V.O., van Schaik, R.H.N., Vletter-Bogaartz, J.M. et al. CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial. Breast Cancer Res Treat 140, 363–373 (2013). https://doi.org/10.1007/s10549-013-2619-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-013-2619-6

Keywords

Search

Navigation